Phase Ib trial of phenformin in patients with V600-mutated melanoma receiving dabrafenib and trametinib.

Paul B Chapman Mark G Klang Michael A Postow Alexander N Shoushtari Ryan J Sullivan Jedd D Wolchok Taha Merghoub Sadna Budhu Phillip Wong Margaret K Callahan Bin Zheng Jonathan H Zippin

Published in: Cancer research communications (2023)

We identified the recommended phase 2 dose of phenformin as 50 mg bid when administered with dabrafenib/trametinib, although some patients will require short drug holidays. We observed a decrease in MDSCs, as predicted by preclinical studies, and may enhance immune recognition of melanoma cells.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
clinical trial
study protocol
randomized controlled trial
cell therapy
bone marrow
skin cancer